SmarterAnalyst
Vertex Pharmaceuticals Announces $1.5B Stock Repurchase Program
The board of Boston-based biopharmaceutical company Vertex Pharmaceuticals (VRTX) has approved a $1.5 billion share repurchase program, per the company’s SEC filing. Vertex develops drugs to treat neurological disorders, autoimmune diseases, infectious diseases, and cystic fibrosis, among others. Under the program, which will run until December 2022, the company will buy back shares via private transactions or on the open market. (See Vertex Pharmaceuticals stock chart on TipRanks) Piper Sandler
